HDAC9 and melanoma: However, HDAC inhibitor monotherapy showed less therapeutic effect combination therapies with HDACis in both HCC and melanoma, which might be attributed to the idea that certain signaling pathways required to activate cell death pathways are only activated by HDACis in drug-resistant cells but not in parental cells [38, 39].